<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01200186</url>
  </required_header>
  <id_info>
    <org_study_id>15217</org_study_id>
    <secondary_id>QL0901</secondary_id>
    <nct_id>NCT01200186</nct_id>
  </id_info>
  <brief_title>Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction</brief_title>
  <official_title>Non-interventional Study on Oral Contraception Not Containing Ethinylestradiol (EE) to Assess Continuation Rates and Satisfaction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, non-interventional, multi-center study. Each subject will be followed for up to
      twelve months during the treatment with oral hormonal contraceptives(Qlaira ® or a Progestin
      Only Pill). For each subject demographic data and medical history will be documented at Visit
      1: (Baseline). Bleeding profile, subjective assessment of study treatment (satisfaction and
      wellbeing) and adverse events including unintended pregnancies will be documented at Visit 2
      (Month 3-5) and Visit 3 (Month 6-12). Data audit/monitoring will be done.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">February 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure will be time-to-event for discontinuation due to bleeding irregularities.</measure>
    <time_frame>up to 12 Months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to event for discontinuation due to reasons other than bleeding irregularities</measure>
    <time_frame>Month 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to event for discontinuation due to reasons other than bleeding irregularities</measure>
    <time_frame>Month 6-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intracyclic bleeding</measure>
    <time_frame>Month 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of intracyclic bleeding</measure>
    <time_frame>Month 6-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of heavy and/or prolonged bleeding</measure>
    <time_frame>Month 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of heavy and/or prolonged bleeding</measure>
    <time_frame>Month 6-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unintended pregnancies</measure>
    <time_frame>Month 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of unintended pregnancies</measure>
    <time_frame>Month 6-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate for the following reasons: Occasional absent or persistent absent withdrawal bleeding , intracyclic bleeding, heavy and/or prolonged bleeding, other medical reasons, non-medical reasons</measure>
    <time_frame>Month 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discontinuation rate for the following reasons: Occasional absent or persistent absent withdrawal bleeding , intracyclic bleeding, heavy and/or prolonged bleeding, other medical reasons, non-medical reasons</measure>
    <time_frame>Month 6-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of well-being and satisfaction</measure>
    <time_frame>Month 3-5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Global assessment of well-being and satisfaction</measure>
    <time_frame>Month 6-12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) at any time point, whether or not related to the therapy or reference therapy</measure>
    <time_frame>up to 12 Months</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">3258</enrollment>
  <condition>Contraceptives, Oral</condition>
  <arm_group>
    <arm_group_label>Group 1</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EV/DNG (Qlaira, BAY86-5027)</intervention_name>
    <description>At the discretion of the attending physician</description>
    <arm_group_label>Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Progestin Only Pills</intervention_name>
    <description>At the discretion of the attending physician</description>
    <arm_group_label>Group 2</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Women in gynecological practice
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women between 18-50 years

          -  Women who used ethinylestradiol containing oral contraceptives for at least the three
             preceding months before the study

          -  Women who decided to start Qlaira® or a Progestin Only Pill. The prescription of the
             hormonal contraceptive is made at the discretion of the attending physician and has to
             be documented

        Exclusion Criteria:

          -  Contraindications and warnings of the respective Summary of Product Characteristics
             (Qlaira® or Progestin Only Pill)

          -  Women who are breast-feeding
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many locations</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Many Locations</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Israel</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
    <country>Norway</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <link>
    <url>http://pharma.bayer.com/en/research-and-development/clinical-trials/trial-finder/index.php</url>
    <description>Click here and search for websynopsis results posting provided by Bayer.</description>
  </link>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 13, 2010</study_first_submitted>
  <study_first_submitted_qc>September 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 13, 2010</study_first_posted>
  <last_update_submitted>October 15, 2015</last_update_submitted>
  <last_update_submitted_qc>October 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Progestins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

